Taken together, our results indicated that the non-kinase domain of SRPK1, a positive regulator directly affecting Wnt/β-catenin pathway, facilitates the regulation of mEGFR levels and tumor growth under gefitinib treatment in NSCLC. This evidence concerns the gene SRPK1 and neoplasm.